Monopar Therapeutics Inc. (MNPR) vs ProKidney Corp. (PROK)
A side-by-side comparison of Monopar Therapeutics Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MNPR
Monopar Therapeutics Inc.
$77.99HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
PROK
ProKidney Corp.
$1.60HealthcareDelayed quote: Oct 6, 2026, 12:30 PM EDT
Total return — MNPR vs PROK
growth of $100 · dividends reinvested · last 5yMNPR +165.8% (+21.6%/yr)PROK -84.4% (-31.0%/yr)MNPR compounded faster over this window
Log scale — wide-divergence pair
MNPR PROK
MNPR vs PROK: by the numbers
- •PROK is the larger company ($536M vs $522M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -10599.76% net margin).
Metrics side by side
Valuation
| Metric | MNPR | PROK |
|---|---|---|
| P/S ratio | N/A | 655.65 |
| P/B ratio | 3.99 | N/A |
Profitability
| Metric | MNPR | PROK |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -18477.83% |
| Net margin | 0.00% | -10599.76% |
| ROE | -13.64% | N/A |
| ROIC | -16.89% | -78.31% |
Growth (annualized)
| Metric | MNPR | PROK |
|---|---|---|
| Total return CAGR (5Y) | 27.38% | -30.65% |
Frequently asked
- How have MNPR and PROK total returns compared?
- Over the past 5 years, MNPR delivered 27.38% and PROK delivered -30.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.